Ongoing Clinical Trials for Adenosquamous Cell Lung Cancer Recurrent
Currently, there are 3 clinical trials underway for adenosquamous cell lung cancer recurrent. These studies are exploring different treatment approaches including immunotherapy combinations, diagnostic testing methods, and personalized cell therapies. The trials are being conducted across several European countries including Germany, Hungary, Czechia, France, and Spain.
Clinical trial locations
- Czechia
- France
- Germany
- Hungary
- Spain
Study on Atezolizumab, Carboplatin, and Etoposide for Adults with Advanced Large-Cell Neuroendocrine Lung Cancer
This trial is testing a combination of immunotherapy and chemotherapy for advanced large-cell neuroendocrine lung cancer. The treatment includes atezolizumab, which helps the immune system fight cancer, along with platinum-based chemotherapy drugs carboplatin or cisplatin and etoposide. All medications are given through an intravenous infusion directly into the bloodstream.
Main inclusion criteria: Patients must be at least 18 years old with a confirmed diagnosis of locally advanced or metastatic large-cell neuroendocrine carcinoma that cannot be cured with surgery. Participants should not have received previous systemic therapy, unless it was given with curative intent and the cancer returned at least 6 months after treatment ended. Patients need to have an ECOG performance status of 0 to 2, meaning they can perform daily activities with some limitations. Adequate organ function is required, including liver and kidney function within acceptable ranges, and sufficient blood cell counts.
Main exclusion criteria: Patients who received other cancer treatment within the last 4 weeks cannot participate. Those with severe allergic reactions to the study drugs, active infections requiring treatment, or other serious medical conditions are excluded. Pregnant or breastfeeding women, patients who participated in another clinical trial within 4 weeks, and those with a history of another cancer type (unless in remission for at least 5 years) are not eligible. Patients with untreated or unstable brain metastases, active autoimmune diseases, or recent drug or alcohol abuse are also excluded.
Focus and goal: The study aims to evaluate how well the combination of atezolizumab with standard chemotherapy works in improving survival for patients with this aggressive type of lung cancer. Researchers will monitor how the cancer responds to treatment, including changes in tumor size and the time it takes for cancer to grow again, while also tracking any side effects.
Investigational drugs: Atezolizumab is an immunotherapy that helps the immune system recognize and attack cancer cells by blocking a protein that allows cancer to hide. Platinum-based drugs like carboplatin and cisplatin work by damaging cancer cell DNA to stop growth. Etoposide is a chemotherapy medication that interferes with DNA inside cancer cells to prevent them from dividing.
Study on the Accuracy of OWL-EVO1 Test for Diagnosing Lung Cancer in Patients Eligible for Screening or with Suspicious CT Findings
This trial is evaluating a new diagnostic test called the OWL-EVO1 Breath Biopsy test. The test analyzes breath samples to help identify whether someone has lung cancer. The study uses a special solution called D5-ethyl-beta-D-glucuronide, given through an intravenous infusion, as part of the testing process.
Main inclusion criteria: Patients must be between 45 and 85 years old and able to understand and consent to participate in the study. They need to have a body mass index between 16 and less than 40, and must have had a CT scan of the chest area within the last 6 months.
Main exclusion criteria: People who are not eligible for lung cancer screening based on low-dose CT scans cannot participate. Those without suspicious findings on their CT scan or whose symptoms do not suggest lung cancer as a possible diagnosis are also excluded.
Focus and goal: The study assesses how accurately the OWL-EVO1 test can differentiate between people who have lung cancer and those who do not. Researchers aim to determine if this breath test can be a reliable tool for diagnosing lung cancer, potentially leading to earlier and more accurate detection. The study also monitors the safety and tolerability of the test.
Investigational drug: OWL-EVO1 is a diagnostic test that analyzes breath samples to detect specific markers that may indicate lung cancer. It works by identifying volatile organic compounds in the breath that can signal the presence of cancer. This non-invasive approach aims to improve diagnostic accuracy for patients undergoing screening or those with suspicious CT scan findings.
Study on the Safety and Effects of ATL001 and Pembrolizumab in Adults with Advanced Non-Small Cell Lung Cancer
This trial explores a personalized cell therapy called ATL001, used alone and in combination with pembrolizumab, an established cancer medication. ATL001 is designed to target specific mutations found in cancer cells. The study focuses on patients with advanced non-small cell lung cancer who have already received standard treatments.
Main inclusion criteria: Patients must be between 18 and 75 years old with a life expectancy of at least 6 months. They should have advanced non-small cell lung cancer that cannot be surgically removed or has spread, and the disease must have progressed after standard treatments or patients cannot receive standard treatments due to side effects. Participants need measurable disease and good overall health status (ECOG 0-1). Before joining, patients must have been treated with a PD-1/PD-L1 inhibitor and experienced disease progression or stable disease after at least four doses. Patients must have adequate organ function and accessible sites of disease for tissue collection. Women of childbearing potential must agree to use effective contraception.
Main exclusion criteria: Patients with other types of cancer besides non-small cell lung cancer cannot participate. Those outside the specified age range, unable to follow study procedures, or with medical conditions that might interfere with the study are excluded. Patients taking medications that could interfere with the study, those who are pregnant or breastfeeding, and those who recently participated in another clinical trial may not be eligible. A history of allergic reactions to the study drugs is also grounds for exclusion.
Focus and goal: The primary aim is to assess the safety and tolerability of ATL001 as a treatment. The study monitors how patients’ cancer responds to treatment and checks for side effects. Researchers will measure changes in tumor size and track how long patients live without their cancer worsening, comparing the effects of the treatment with those of a placebo.
Investigational drugs: ATL001 is a personalized cell therapy that uses specially designed immune cells called T cells to recognize and attack cancer cells. It is administered through infusion and aims to help the immune system fight cancer. Pembrolizumab is an immunotherapy medication that blocks a protein called PD-1, preventing cancer cells from hiding from the immune system. When used together, these treatments aim to provide an enhanced approach to fighting advanced non-small cell lung cancer.
Summary
The three ongoing clinical trials for adenosquamous cell lung cancer recurrent represent diverse approaches to improving diagnosis and treatment. These studies span across multiple European countries, with Germany hosting two trials and France, Spain, Hungary, and Czechia each participating in at least one study.
The trials explore different aspects of lung cancer management. One focuses on combining immunotherapy with standard chemotherapy to improve survival rates in aggressive forms of lung cancer. Another investigates a novel diagnostic breath test that could provide a non-invasive way to detect cancer earlier. The third trial examines personalized cell therapy approaches that target specific cancer mutations, representing a shift toward more individualized treatment strategies.
All three studies involve immunotherapy or immune system-related approaches, reflecting current trends in cancer research that harness the body’s natural defenses. The trials include both early-phase safety studies and later-stage effectiveness evaluations, contributing to a comprehensive understanding of new treatment possibilities. Patients interested in participating should discuss eligibility requirements with their healthcare providers, as each study has specific criteria based on disease stage, previous treatments, and overall health status.
